MDS experts, Dr Alan List and Dr David Sallman, provide an overview of the prognostic classification systems for myelodysplastic syndromes (MDS) that are used to predict outlook and decide on treatment options. The International Prognostic Scoring System (IPSS) and the Revised International Prognostic Scoring System (IPSS-R) help determine if a patient has a lower risk or a higher risk of their MDS progressing into acute myeloid leukemia, and help doctors plan treatment.
This educational activity has been developed by
the Myelodysplastic Syndromes Foundation, Inc and Mechanisms in Medicine Inc.
This activity is supported by charitable grants from Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their health care professionals for optimal outcomes.